A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Inclusion Criteria:

- Have a definite clinical diagnosis of stable (at least 6 months) plaque psoriasis,
involving at least 2% and no more than 20% of the body surface area (BSA) (not
including the scalp and intertriginous areas)

- Have a minimum plaque elevation at the target lesion site of at least moderate
severity (grade ≥ 3 on the Psoriasis Area Severity Index [PASI]). The most severe
lesion at baseline should be identified as the target lesion

- Have an Investigator's Global Assessment (IGA) of disease severity of at least
moderate (score ≥ 3) as an overall assessment of all lesions to be treated.

Exclusion Criteria:

- A female subject who is pregnant, nursing, planning a pregnancy, or does not agree to
use an acceptable form of birth control within the study participation period

- Have a current diagnosis of unstable forms of psoriasis in the treatment area,
including pustular, guttate, exfoliative or erythrodermic psoriasis

- Have a history of psoriasis unresponsive to topical treatments